Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma.

@article{Riestra1998TamoxifenDN,
  title={Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma.},
  author={Sabino Riestra and Manuel T Rodriguez and M del M Delgado and Avelina Su{\'a}rez and Nicolas Gonzalez and Manuel de la Mata and Gloria D{\'i}az and G Mi{\~n}o-Fugarolas and Luis Rodrigo},
  journal={Journal of clinical gastroenterology},
  year={1998},
  volume={26 3},
  pages={200-3}
}
To discover whether tamoxifen is able to extend the survival of patients with advanced hepatocellular carcinoma, we included 80 patients with cirrhosis and advanced hepatocellular carcinoma in a multicenter, double-blind, placebo-controlled trial in order to analyze the influence of treatment with tamoxifen on survival. The patients were randomized to receive tamoxifen, 40 mg/day (group 1), or placebo (group 2). Both groups were similar in age, sex, etiology of cirrhosis, biochemical… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Hepatocellular carcinoma

Nature Reviews Disease Primers • 2016

Similar Papers

Loading similar papers…